Cerebral small vessel disease: Capillary pathways to stroke and cognitive decline

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 2, 2016, Pages 302-325

  Østergaard, Leif ^a,b   Engedal, Thorbjørn S ^a   Moreton, Fiona ^c   Hansen, Mikkel B ^a   Wardlaw, Joanna M ^d   Dalkara, Turgay ^e   Markus, Hugh S ^f   Muir, Keith W ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e HACETTEPE UNIVERSITY   (Turkey)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

capillary dysfunction; Cerebral small vessel disease; dementia; oxygenation; stroke

Indexed keywords

AMYLOID; HEMOGLOBIN; NICOTINE; NITROGEN OXIDE; OXYGEN; PHOSPHODIESTERASE INHIBITOR;

ANEMIA; BLOOD VISCOSITY; BRAIN BLOOD FLOW; BRAIN CAPILLARY; BRAIN CAPILLARY ENDOTHELIUM; BRAIN PERICYTE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; ENDOTHELIAL DYSFUNCTION; GLYCOCALYX; HUMAN; HYPEREMIA; MENTAL DETERIORATION; META ANALYSIS (TOPIC); NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; CAPILLARY; CEREBROVASCULAR DISEASE; COGNITION DISORDERS; COMPLICATION; DISEASE COURSE; PATHOLOGY; PSYCHOLOGY; STROKE;

CAPILLARIES; CEREBRAL SMALL VESSEL DISEASES; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; STROKE;

EID: 84961374240     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X15606723     Document Type: Review

References (247)

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689-701.
2. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822-838.
3. Wardlaw JM, Doubal FN, Valdes-Hernandez M, et al. Blood-brain barrier permeability and long-Term clinical and imaging outcomes in cerebral small vessel disease. Stroke 2013; 44: 525-527.
4. Wardlaw JM, Smith C and Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013; 12: 483-497.
5. Jespersen SN and Ostergaard L. The roles of cerebral blood flow, capillary transit time heterogeneity and oxygen tension in brain oxygenation and metabolism. J Cereb Blood Flow Metab 2012; 32: 264-277.
6. Ostergaard L, Jespersen SN, Mouridsen K, et al. The role of the cerebral capillaries in acute ischemic stroke: the extended penumbra model. J Cereb Blood Flow Metab 2013; 33: 635-648.
7. Ostergaard L, Aamand R, Gutierrez-Jimenez E, et al. The capillary dysfunction hypothesis of Alzheimer?s disease. Neurobiol Aging 2013; 34: 1018-1031.
8. Baron JC, Bousser MG, Comar D, et al. Noninvasive tomographic study of cerebral blood flow and oxygen metabolism in vivo. Potentials, limitations, and clinical applications in cerebral ischemic disorders. Eur Neurol 1981; 20: 273-284.
9. Renkin EM. Regulation of the microcirculation. Microvasc Res 1985; 30: 251-263. (B. W. Zweifach Award lecture.
10. Kleinfeld D, Mitra PP, Helmchen F, et al. Fluctuations and stimulus-induced changes in blood flow observed in individual capillaries in layers 2 through 4 of rat neocortex. Proc Natl Acad Sci U S A 1998; 95: 15741-15746.
11. Villringer A, Them A, Lindauer U, et al. Capillary perfusion of the rat brain cortex. An in vivo confocal microscopy study. Circ Res 1994; 75: 55-62.
12. Stefanovic B, Hutchinson E, Yakovleva V, et al. Functional reactivity of cerebral capillaries. J Cereb Blood Flow Metab 2008; 28: 961-972.
13. Ostergaard L, Chesler DA, Weisskoff RM, et al. Modeling cerebral blood flow and flow heterogeneity from magnetic resonance residue data. J Cereb Blood Flow Metab 1999; 19: 690-699.
14. Ostergaard L, Sorensen AG, Chesler DA, et al. Combined diffusion-weighted and perfusion-weighted flow heterogeneity magnetic resonance imaging in acute stroke. Stroke 2000; 31: 1097-1103.
15. Schulte ML, Wood JD and Hudetz AG. Cortical electrical stimulation alters erythrocyte perfusion pattern in the cerebral capillary network of the rat. Brain Res 2003; 963: 81-92.
16. Vogel J and Kuschinsky W. Decreased heterogeneity of capillary plasma flow in the rat whisker-barrel cortex during functional hyperemia. J Cereb Blood Flow Metab 1996; 16: 1300-1306.
17. Rasmussen PM, Jespersen SN and Ostergaard L. The effects of transit time heterogeneity on brain oxygenation during rest and functional activation. J Cereb Blood Flow Metab 2015; 35: 432-442.
18. Peppiatt CM, Howarth C, Mobbs P, et al. Bidirectional control of CNS capillary diameter by pericytes. Nature 2006; 443: 700-704.
19. Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 2014; 508: 55-60.
20. Ostergaard L. Cerebral perfusion imaging by bolus tracking. Top Magn Reson Imaging 2004; 15: 3-9.
21. Angleys H, Ostergaard L and Jespersen SN. The effects of capillary transit time heterogeneity (cth) on brain oxygenation. J Cereb Blood Flow Metab 2015; 35: 806-817.
22. Donnan GA, Baron JC, Davis SM, et al. The ischemic penumbra: overview, definition, and criteria. In: Donnan GA, Baron JC, Davis SM, et al. (eds) The Ischemic Penumbra. New York: Informa Healthcare USA, 2007, pp.7-20.
23. Lassen NA. The luxury-perfusion syndrome and its possible relation to acute metabolic acidosis localised within the brain. Lancet 1966; 2: 1113-1115.
24. Yemisci M, Gursoy-Ozdemir Y, Vural A, et al. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med 2009; 15: 1031-1037.
25. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11.
26. Younger DS. Vasculitis of the nervous system. Curr Opin Neurol 2004; 17: 317-336.
27. Armulik A, Abramsson A and Betsholtz C. Endothelial/ pericyte interactions. Circ Res 2005; 97: 512-523.
28. Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature 2010; 468: 557-561.
29. Thomas WE. Brain macrophages: on the role of pericytes and perivascular cells. Brain Res Brain Res Rev 1999; 31: 42-57.
30. Dore-Duffy P and LaManna JC. Physiologic angiodynamics in the brain. Antioxid Redox Signal 2007; 9: 1363-1371.
31. Domenga V, Fardoux P, Lacombe P, et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004; 18: 2730-2735.
32. Morrow D, Sweeney C, Birney YA, et al. Cyclic strain inhibits Notch receptor signaling in vascular smooth muscle cells in vitro. Circ Res 2005; 96: 567-575.
33. Boulos N, Helle F, Dussaule JC, et al. Notch3 is essential for regulation of the renal vascular tone. Hypertension 2011; 57: 1176-1182.
34. Hill RA, Tong L, Yuan P, et al. Regional blood flow in the normal and ischemic brain is controlled by arteriolar smooth muscle cell contractility and not by capillary pericytes. Neuron 2015; 87: 95-110.
35. Fernandez-Klett F, Offenhauser N, Dirnagl U, et al. Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc Natl Acad Sci U S A 2010; 107: 22290-22295.
36. Attwell D. Comments to: smooth muscle cells, not pericytes, control brain blood flow. http://www.alzforum org/news/research-news/smooth-muscle-cells-not-pericytes-control-brain-blood-flow (2015, accessed 19 July 2015).
37. Yamanishi S, Katsumura K, Kobayashi T, et al. Extracellular lactate as a dynamic vasoactive signal in the rat retinal microvasculature. Am J Physiol Heart Circ Physiol 2006; 290: H925-H934.
38. Kawamura H, Kobayashi M, Li Q, et al. Effects of angiotensin II on the pericyte-containing microvasculature of the rat retina. J Physiol 2004; 561: 671-683.
39. Schonfelder U, Hofer A, Paul M, et al. In situ observation of living pericytes in rat retinal capillaries. Microvasc Res 1998; 56: 22-29.
40. Diaz-Flores L, Gutierrez R, Madrid JF, et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol 2009; 24: 909-969.
41. Matsugi T, Chen Q and Anderson DR. Adenosineinduced relaxation of cultured bovine retinal pericytes. Invest Ophthalmol Vis Sci 1997; 38: 2695-2701.
42. Kawamura H, Sugiyama T, Wu DM, et al. ATP: a vasoactive signal in the pericyte-containing microvasculature of the rat retina. J Physiol 2003; 551: 787-799.
43. Haefliger IO, Zschauer A and Anderson DR. Relaxation of retinal pericyte contractile tone through the nitric oxide-cyclic guanosine monophosphate pathway. Invest Ophthalmol Vis Sci 1994; 35: 991-997.
44. Haefliger IO and Anderson DR. Oxygen modulation of guanylate cyclase-mediated retinal pericyte relaxations with 3-morpholino-sydnonimine and atrial natriuretic peptide. Invest Ophthalmol Vis Sci 1997; 38: 1563-1568.
45. Wu DM, Kawamura H, Sakagami K, et al. Cholinergic regulation of pericyte-containing retinal microvessels. Am J Physiol Heart Circ Physiol 2003; 284: H2083-H2090.
46. Attwell D, Buchan AM, Charpak S, et al. Glial and neuronal control of brain blood flow. Nature 2010; 468: 232-243.
47. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996; 383: 707-710.
48. Joutel A, Andreux F, Gaulis S, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 2000; 105: 597-605.
49. Dziewulska D and Lewandowska E. Pericytes as a new target for pathological processes in CADASIL. Neuropathology 2012; 32: 515-521.
50. Joutel A, Monet-Lepretre M, Gosele C, et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest 2010; 120: 433-445.
51. Gu X, Liu XY, Fagan A, et al. Ultrastructural changes in cerebral capillary pericytes in aged Notch3 mutant transgenic mice. Ultrastruct Pathol 2012; 36: 48-55.
52. Wang Y, Pan L, Moens CB, et al. Notch3 establishes brain vascular integrity by regulating pericyte number. Development 2014; 141: 307-317.
53. Hill J, Rom S, Ramirez SH, et al. Emerging roles of pericytes in the regulation of the neurovascular unit in health and disease. J Neuroimmune Pharmacol 2014; 9: 591-605.
54. Wang S, Cao C, Chen Z, et al. Pericytes regulate vascular basement membrane remodeling and govern neutrophil extravasation during inflammation. PLoS One 2012; 7: e45499.
55. Dore-Duffy P, Owen C, Balabanov R, et al. Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res 2000; 60: 55-69.
56. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 2012; 4: 147ra111.
57. Carare RO, Bernardes-Silva M, Newman TA, et al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008; 34: 131-144.
58. Kress BT, Iliff JJ, Xia M, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 2014; 76: 845-861.
59. Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer?s disease. Brain Pathol 2008; 18: 253-266.
60. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer?s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489-1499.
61. Ball KK, Cruz NF, Mrak RE, et al. Trafficking of glucose, lactate, and amyloid-beta from the inferior colliculus through perivascular routes. J Cereb Blood Flow Metab 2010; 30: 162-176.
62. Verbeek MM, de Waal RM, Schipper JJ, et al. Rapid degeneration of cultured human brain pericytes by amyloid beta protein. J Neurochem 1997; 68: 1135-1141.
63. Wilhelmus MMM, Otte-Höller I, van Triel JJJ, et al. Lipoprotein receptor-related protein-1 mediates amyloid-b-mediated cell death of cerebrovascular cells. Am J Pathol 2007; 171: 1989-1999.
64. Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012; 485: 512-516.
65. Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68: 409-427.
66. Hamilton NB, Attwell D and Hall CN. Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Frontiers in Neuroenergetics 2010; 2: 1-15.
67. Winkler EA, Bell RD and Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci 2011; 14: 1398-1405.
68. Macdonald RL and Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 1991; 22: 971-982.
69. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther 2005; 105: 23-56.
70. Gryglewski RJ, Palmer RM and Moncada S. Superoxide anion is involved in the breakdown of endotheliumderived vascular relaxing factor. Nature 1986; 320: 454-456.
71. Rey FE, Li XC, Carretero OA, et al. Perivascular superoxide anion contributes to impairment of endotheliumdependent relaxation: role of gp91(phox). Circulation 2002; 106: 2497-2502.
72. Sasaki T, Wakai S, Asano T, et al. The effect of a lipid hydroperoxide of arachidonic acid on the canine basilar artery. An experimental study on cerebral vasospasm. J Neurosurg 1981; 54: 357-365.
73. Pyne-Geithman GJ, Nair SG, Stamper DN, et al. Role of bilirubin oxidation products in the pathophysiology of DIND following SAH. Acta Neurochir Suppl 2013; 115: 267-273.
74. Isakson BE, Damon DN, Day KH, et al. Connexin40 and connexin43 in mouse aortic endothelium: evidence for coordinated regulation. Am J Physiol Heart Circ Physiol 2006; 290: H1199-H1205.
75. Segal SS and Duling BR. Conduction of vasomotor responses in arterioles: a role for cell-To-cell coupling?. Am J Physiol 1989; 256: H838-H845.
76. Segal SS and Duling BR. Flow control among microvessels coordinated by intercellular conduction. Science 1986; 234: 868-870.
77. Duling BR and Berne RM. Propagated vasodilation in the microcirculation of the hamster cheek pouch. Circ Res 1970; 26: 163-170.
78. Pries AR, Hopfner M, le Noble F, et al. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 2010; 10: 587-593.
79. Woywodt A, Streiber F, de Groot K, et al. Circulating endothelial cells as markers for ANCA-Associated smallvessel vasculitis. Lancet 2003; 361: 206-210.
80. Vink H and Duling BR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 1996; 79: 581-589.
81. Pries AR, Secomb TW and Gaehtgens P. The endothelial surface layer. Pflugers Arch 2000; 440: 653-666.
82. Secomb TW, Hsu R and Pries AR. A model for red blood cell motion in glycocalyx-lined capillaries. Am J Physiol 1998; 274: H1016-H1022.
83. Constantinescu AA, Vink H and Spaan JA. Elevated capillary tube hematocrit reflects degradation of endothelial cell glycocalyx by oxidized LDL. Am J Physiol Heart Circ Physiol 2001; 280: H1051-H1057.
84. Desjardins C and Duling BR. Heparinase treatment suggests a role for the endothelial cell glycocalyx in regulation of capillary hematocrit. Am J Physiol 1990; 258: H647-H654.
85. van Haaren PM, VanBavel E, Vink H, et al. Localization of the permeability barrier to solutes in isolated arteries by confocal microscopy. Am J Physiol Heart Circ Physiol 2003; 285: H2848-H2856.
86. van den Berg BM, Vink H and Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res 2003; 92: 592-594.
87. Vink H, Constantinescu AA and Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-Endothelial cell adhesion. Circulation 2000; 101: 1500-1502.
88. Czarnowska E and Karwatowska-Prokopczuk E. Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Involvement of oxygen free radicals. Basic Res Cardiol 1995; 90: 357-364.
89. Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006; 55: 1127-1132.
90. Ishiharajima S, Aida T, Nakagawa R, et al. Early membrane damage during ischemia in rat heart. Exp Mol Pathol 1986; 44: 1-6.
91. Mazzoni MC and Schmid-Schonbein GW. Mechanisms and consequences of cell activation in the microcirculation. Cardiovasc Res 1996; 32: 709-719.
92. Barnes AJ, Locke P and Scudder PR. Is hyperviscosity a treatable component of diabetic microcirculatory disease?. Lancet 1977; 2: 789-791.
93. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer?s disease. Nat Rev Neurosci 2004; 5: 347-360.
94. Al-Saeedi FJ. Perfusion scanning using 99mTc-HMPAO detects early cerebrovascular changes in the diabetic rat. BMC Med Phys 2008; 8: 1.
95. Simpson RE III, Phillis JW and Buchannan J. A comparison of cerebral blood flow during basal, hypotensive, hypoxic and hypercapnic conditions between normal and streptozotocin diabetic rats. Brain Res 1990; 531: 136-142.
96. Rubin MJ and Bohlen HG. Cerebral vascular autoregulation of blood flow and tissue PO2 in diabetic rats. Am J Physiol 1985; 249: H540-H546.
97. Kim T, Richard Jennings J and Kim SG. Regional cerebral blood flow and arterial blood volume and their reactivity to hypercapnia in hypertensive and normotensive rats. J Cereb Blood Flow Metab 2014; 34: 408-414.
98. Thal DR, Papassotiropoulos A, Saido TC, et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-Associated subtype of sporadic Alzheimer?s disease. Acta Neuropathol 2010; 120: 169-183.
99. Scarmeas N, Habeck CG, Stern Y, et al. APOE genotype and cerebral blood flow in healthy young individuals. JAMA 2003; 290: 1581-1582.
100. Scarmeas N, Habeck CG, Hilton J, et al. APOE related alterations in cerebral activation even at college age. J Neurol Neurosurg Psychiatry 2005; 76: 1440-1444.
101. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer?s disease. N Engl J Med 2000; 343: 450-456.
102. Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOEepsilon4 allele. Proc Natl Acad Sci U S A 2009; 106: 7209-7214.
103. Fleisher AS, Houston WS, Eyler LT, et al. Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol 2005; 62: 1881-1888.
104. DiFrancesco MW, Holland SK, Ris MD, et al. Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. Arthritis Rheum 2007; 56: 4151-4163.
105. Ernst T, Chang L, Jovicich J, et al. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002; 59: 1343-1349.
106. Ernst T, Chang L and Arnold S. Increased glial metabolites predict increased working memory network activation in HIV brain injury. Neuroimage 2003; 19: 1686-1693.
107. Ances BM, Roc AC, Korczykowski M, et al. Combination antiretroviral therapy modulates the blood oxygen level-Dependent amplitude in human immunodeficiency virus-seropositive patients. J Neurovirol 2008; 14: 418-424.
108. Buxton RB. Dynamic models of BOLD contrast. Neuroimage 2012; 62: 953-961.
109. Thambisetty M, Beason-Held L, An Y, et al. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol 2010; 67: 93-98.
110. Fleisher AS, Podraza KM, Bangen KJ, et al. Cerebral perfusion and oxygenation differences in Alzheimer?s disease risk. Neurobiol Aging 2009; 30: 1737-1748.
111. Calcinaghi N, Wyss MT, Jolivet R, et al. Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension. Stroke 2013; 44: 1957-1964.
112. Suri S, Mackay CE, Kelly ME, et al. Reduced cerebrovascular reactivity in young adults carrying the APOE epsilon4 allele. Alzheimers Dement 2015; 11: 648-657.
113. Girouard H and Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 2006; 100: 328-335.
114. Kazama K, Wang G, Frys K, et al. Angiotensin II attenuates functional hyperemia in the mouse somatosensory cortex. Am J Physiol Heart Circ Physiol 2003; 285: H1890-H1899.
115. Niwa K, Younkin L, Ebeling C, et al. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A 2000; 97: 9735-9740.
116. Capone C, Faraco G, Park L, et al. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol 2011; 300: H397-H407.
117. Kazama K, Anrather J, Zhou P, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-Derived radicals. Circ Res 2004; 95: 1019-1026.
118. Girouard H, Park L, Anrather J, et al. Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vasc Biol 2007; 27: 303-309.
119. Dawson VL and Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat 1996; 10: 179-190.
120. Pacher P, Beckman JS and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424.
121. Touyz RM and Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122: 339-352.
122. Sakadzic S, Mandeville ET, Gagnon L, et al. Large arteriolar component of oxygen delivery implies a safe margin of oxygen supply to cerebral tissue. Nat Commun 2014; 5: 5734.
123. Moody DM, Brown WR, Challa VR, et al. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer?s disease. Ann N Y Acad Sci 1997; 826: 103-116.
124. Doubal FN, MacGillivray TJ, Hokke PE, et al. Differences in retinal vessels support a distinct vasculopathy causing lacunar stroke. Neurology 2009; 72: 1773-1778.
125. Lindley RI, Wang JJ, Wong MC, et al. Retinal microvasculature in acute lacunar stroke: a cross-sectional study. Lancet Neurol 2009; 8: 628-634.
126. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33: 525-531.
127. Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001; 104: 1506-1512.
128. Moore DF, Herscovitch P and Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 2001; 11: 303-307.
129. Moore DF, Altarescu G, Barker WC, et al. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003; 62: 231-240.
130. Sano M, Ishii K, Momose Y, et al. Cerebral metabolism of oxygen and glucose in a patient with MELAS syndrome. Acta Neurol Scand 1995; 92: 497-502.
131. Takahashi S, Tohgi H, Yonezawa H, et al. Cerebral blood flow and oxygen metabolism before and after a stroke-like episode in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes (MELAS). J Neurol Sci 1998; 158: 58-64.
132. Wang Z, Xiao J, Xie S, et al. MR evaluation of cerebral oxygen metabolism and blood flow in stroke-like episodes of MELAS. J Neurol Sci 2012; 323: 173-177.
133. Yu L, Xie S, Xiao J, et al. Quantitative measurement of cerebral oxygen extraction fraction using MRI in patients with MELAS. PLoS One 2013; 8: e79859.
134. Gropen TI, Prohovnik I, Tatemichi TK, et al. Cerebral hyperemia in MELAS. Stroke 1994; 25: 1873-1876.
135. Amagasaki K, Shimizu T, Suzuki Y, et al. Focal hyperperfusion in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Case report. J Neurosurg 2001; 94: 133-136.
136. Warrington JP, Ashpole N, Csiszar A, et al. Whole brain radiation-induced vascular cognitive impairment: mechanisms and implications. J Vasc Res 2013; 50: 445-457.
137. Warrington JP, Csiszar A, Johnson DA, et al. Cerebral microvascular rarefaction induced by whole brain radiation is reversible by systemic hypoxia in mice. Am J Physiol Heart Circ Physiol 2011; 300: H736-H744.
138. Mineura K, Suda Y, Yasuda T, et al. Early and late stage positron emission tomography (PET) studies on the haemocirculation and metabolism of seemingly normal brain tissue in patients with gliomas following radiochemotherapy. Acta Neurochir (Wien) 1988; 93: 110-115.
139. Hahn CA, Zhou SM, Raynor R, et al. Dose-Dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. Int J Radiat Oncol Biol Phys 2009; 73: 1082-1087.
140. Ostergaard L, Jespersen SN, Engedal TS, et al. Capillary dysfunction: its detection and causative role in dementias and stroke. Curr Neurol Neurosci Rep 2015; 15: 557.
141. Ferraccioli G, Di Poi E, Di Gregorio F, et al. Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud?s syndrome. Lancet 1999; 354: 2135-2136.
142. Wardlaw JM. What causes lacunar stroke?. J Neurol Neurosurg Psychiatry 2005; 76: 617-619.
143. Hassan A, Gormley K, O?Sullivan M, et al. Endothelial nitric oxide gene haplotypes and risk of cerebral smallvessel disease. Stroke 2004; 35: 654-659.
144. Yemisci M, Sinici I, Ozkara HA, et al. Protective role of 27bp repeat polymorphism in intron 4 of eNOS gene in lacunar infarction. Free Radic Res 2009; 43: 272-279.
145. van Faassen EE, Bahrami S, Feelisch M, et al. Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev 2009; 29: 683-741.
146. Aamand R, Dalsgaard T, Ho YC, et al. A NO way to BOLD?. Dietary nitrate alters the hemodynamic response to visual stimulation. Neuroimage 2013; 83: 397-407.
147. Patterson JL Jr, Heyman A and Nichols Jr. F.T. Cerebral blood flow and oxygen consumption in neurosyphilis. J Clin Invest 1950; 29: 1327-1334.
148. Logigian EL, Johnson KA, Kijewski MF, et al. Reversible cerebral hypoperfusion in Lyme encephalopathy. Neurology 1997; 49: 1661-1670.
149. Dickinson J and Paton JFR. Cerebrovascular hypertension. Brighton, UK: Book Guild Publishing, 2012.
150. Scheinker IM. Alterations of cerebral capillaries in the early stage of arterial hypertension. Am J Pathol 1948; 24: 211-221.
151. Soros P, Whitehead S, Spence JD, et al. Antihypertensive treatment can prevent stroke and cognitive decline. Nat Rev Neurol 2013; 9: 174-178.
152. Knudsen GM, Pettigrew KD, Paulson OB, et al. Kinetic analysis of blood-brain barrier transport of D-glucose in man: quantitative evaluation in the presence of tracer backflux and capillary heterogeneity. Microvasc Res 1990; 39: 28-49.
153. Simpson IA, Carruthers A and Vannucci SJ. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 2007; 27: 1766-1791.
154. Ostergaard L. Principles of cerebral perfusion imaging by bolus tracking. J Magn Reson Imaging 2005; 22: 710-717.
155. Ellis CG, Goldman D, Hanson M, et al. Defects in oxygen supply to skeletal muscle of prediabetic ZDF rats. Am J Physiol Heart Circ Physiol 2010; 298: H1661-H1670.
156. Domenech M, Roman P, Lapetra J, et al. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial. Hypertension 2014; 64: 69-76.
157. Ostergaard L, Tietze A, Nielsen T, et al. The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Cancer Res 2013; 73: 5618-5624.
158. Lavallee P, Perchaud V, Gautier-Bertrand M, et al. Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002; 33: 513-518.
159. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322-1332.
160. Grau AJ, Fischer B, Barth C, et al. Influenza vaccination is associated with a reduced risk of stroke. Stroke 2005; 36: 1501-1506.
161. Kountouras J, Boziki M, Gavalas E, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer?s disease. J Neurol 2009; 256: 758-767.
162. Kountouras J, Boziki M, Gavalas E, et al. Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol 2010; 23: 199-204.
163. Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281: 2113-2118.
164. Hassan A, Hunt BJ, O?Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004; 127: 212-219.
165. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-Analysis of genetic studies and randomised trials. Lancet 2011; 378: 584-594.
166. Horlington M and Watson PA. Inhibition of 3050-cyclic-AMP phosphodiesterase by some platelet aggregation inhibitors. Biochem Pharmacol 1970; 19: 955-956.
167. Jacoby D and Mohler ER III. Drug treatment of intermittent claudication. Drugs 2004; 64: 1657-1670.
168. Bath PM and Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke 2015; 10: 469-478.
169. Albaugh G, Bellavance E, Strande L, et al. Nicotine induces mononuclear leukocyte adhesion and expression of adhesion molecules, VCAM and ICAM, in endothelial cells in vitro. Ann Vasc Surg 2004; 18: 302-307.
170. Yong T, Zheng MQ and Linthicum DS. Nicotine induces leukocyte rolling and adhesion in the cerebral microcirculation of the mouse. J Neuroimmunol 1997; 80: 158-164.
171. Petri B, Phillipson M and Kubes P. The physiology of leukocyte recruitment: an in vivo perspective. J Immunol 2008; 180: 6439-6446.
172. Adib-Samii P, Brice G, Martin RJ, et al. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke 2010; 41: 630-634.
173. Staals J, Makin SD, Doubal FN, et al. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology 2014; 83: 1228-1234.
174. Marin JM, Carrizo SJ, Vicente E, et al. Long-Term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
175. Davis DH, Muniz Terrera G, Keage H, et al. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain 2012; 135: 2809-2816.
176. Gardener H, Scarmeas N, Gu Y, et al. Mediterranean diet and white matter hyperintensity volume in the Northern Manhattan Study. Arch Neurol 2012; 69: 251-256.
177. Gardener H, Wright CB, Gu Y, et al. Mediterraneanstyle diet and risk of ischemic stroke, myocardial infarction, and vascular death: the Northern Manhattan Study. Am J Clin Nutr 2011; 94: 1458-1464.
178. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-1290.
179. Gaudin A, Yemisci M, Eroglu H, et al. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nat Nanotechnol 2014; 9: 1054-1062.
180. Powers WJ, Clarke WR, Grubb RL Jr, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 2011; 306: 1983-1992.
181. Dani KA, Thomas RG, Chappell FM, et al. Computed tomography and magnetic resonance perfusion imaging in ischemic stroke: definitions and thresholds. Ann Neurol 2011; 70: 384-401.
182. Mouridsen K, Hansen MB, Ostergaard L, et al. Reliable estimation of capillary transit time distributions using DSC-MRI. J Cereb Blood Flow Metab 2014; 34: 1511-1521.
183. Zlokovic BV, Deane R, Sagare AP, et al. Low-Density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer?s amyloid beta-peptide elimination from the brain. J Neurochem 2010; 115: 1077-1089.
184. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer?s disease and other disorders. Nat Rev Neurosci 2011; 12: 723-738.
185. Dalkara T, Gursoy-Ozdemir Y and Yemisci M. Brain microvascular pericytes in health and disease. Acta Neuropathol 2011; 122: 1-9.
186. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-Delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009; 15: 1298-1306.
187. Sette G, Baron JC, Mazoyer B, et al. Local brain haemodynamics and oxygen metabolism in cerebrovascular disease. Positron emission tomography. Brain 1989; 112 (Pt 4): 931-951.
188. Farkas E, de Vos RA, Donka G, et al. Age-related microvascular degeneration in the human cerebral periventricular white matter. Acta Neuropathol 2006; 111: 150-157.
189. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68: 711-722.
190. Farkas E and Luiten PG. Cerebral microvascular pathology in aging and Alzheimer?s disease. Prog Neurobiol 2001; 64: 575-611.
191. Sakuta R and Nonaka I. Vascular involvement in mitochondrial myopathy. Ann Neurol 1989; 25: 594-601.
192. Ohama E, Ohara S, Ikuta F, et al. Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol 1987; 74: 226-233.
193. Weisskoff RM, Zuo CS, Boxerman JL, et al. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med 1994; 31: 601-610.
194. Kalaria RN. Cerebral vessels in ageing and Alzheimer?s disease. Pharmacol Ther 1996; 72: 193-214.
195. Bell MA and Ball MJ. Morphometric comparison of hippocampal microvasculature in ageing and demented people: diameters and densities. Acta Neuropathol 1981; 53: 299-318.
196. Junker U, Jaggi C, Bestetti G, et al. Basement membrane of hypothalamus and cortex capillaries from normotensive and spontaneously hypertensive rats with streptozotocin-induced diabetes. Acta Neuropathol 1985; 65: 202-208.
197. Tagami M, Nara Y, Kubota A, et al. Ultrastructural changes in cerebral pericytes and astrocytes of strokeprone spontaneously hypertensive rats. Stroke 1990; 21: 1064-1071.
198. Johnson PC, Brendel K and Meezan E. Thickened cerebral cortical capillary basement membranes in diabetics. Arch Pathol Lab Med 1982; 106: 214-217.
199. Reske-Nielsen E, Lundbæk K and Rafaelsen OJ. Pathological changes in the central and peripheral nervous system of young long-Term diabetics. I. Diabetic encephalopathy. Diabetologia 1965; 1: 233-241.
200. McCuskey PA and McCuskey RS. In vivo and electron microscopic study of the development of cerebral diabetic microangiography. Microcirc Endothelium Lymphatics 1984; 1: 221-244.
201. Price TO, Eranki V, Banks WA, et al. Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology 2012; 153: 362-372.
202. Shah GN, Price TO, Banks WA, et al. Pharmacological inhibition of mitochondrial carbonic anhydrases protects mouse cerebral pericytes from high glucoseinduced oxidative stress and apoptosis. J Pharmacol Exp Ther 2013; 344: 637-645.
203. Low WC, Junna M, Borjesson-Hanson A, et al. Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL. Brain 2007; 130: 357-367.
204. Tikka S, Mykkanen K, Ruchoux MM, et al. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain 2009; 132: 933-939.
205. Yamamoto Y, Craggs LJ, Watanabe A, et al. Brain microvascular accumulation and distribution of the NOTCH3 ectodomain and granular osmiophilic material in CADASIL. J Neuropathol Exp Neurol 2013; 72: 416-431.
206. Mizukami K, Sasaki M, Suzuki T, et al. Central nervous system changes in mitochondrial encephalomyopathy: light and electron microscopic study. Acta Neuropathol 1992; 83: 449-452.
207. Koo B, Becker LE, Chuang S, et al. Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS): clinical, radiological, pathological, and genetic observations. Ann Neurol 1993; 34: 25-32.
208. Lou HO and Reske-Nielsen E. the central nervous system in Fabry?s disease. A clinical, pathological, and biochemical investigation. Arch Neurol 1971; 25: 351-359.
209. Grunnet ML and Spilsbury PR. The central nervous system in Fabry?s disease. An ultrastructural study. Arch Neurol 1973; 28: 231-234.
210. Itoh Y, Esaki T, Cook M, et al. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. J Neurochem 2001; 79: 1217-1224.
211. Weil S, Reifenberger G, Dudel C, et al. Cerebroretinal vasculopathy mimicking a brain tumor: a case of a rare hereditary syndrome. Neurology 1999; 53: 629-631.
212. Altarescu G, Moore DF, Pursley R, et al. Enhanced endothelium-Dependent vasodilation in Fabry disease. Stroke 2001; 32: 1559-1562.
213. Cohn AC, Kotschet K, Veitch A, et al. Novel ophthalmological features in hereditary endotheliopathy with retinopathy, nephropathy and stroke syndrome. Clin Experiment Ophthalmol 2005; 33: 181-183.
214. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49: 1322-1330.
215. Gould DB, Phalan FC, van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006; 354: 1489-1496.
216. Poschl E, Schlotzer-Schrehardt U, Brachvogel B, et al. Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development 2004; 131: 1619-1628.
217. Hagel C, Groden C, Niemeyer R, et al. Subcortical angiopathic encephalopathy in a German kindred suggests an autosomal dominant disorder distinct from CADASIL. Acta Neuropathol 2004; 108: 231-240.
218. Craggs LJ, Hagel C, Kuhlenbaeumer G, et al. Quantitative vascular pathology and phenotyping familial and sporadic cerebral small vessel diseases. Brain Pathol 2013; 23: 547-557.
219. Halbwachs L and Lesavre P. Endothelium-neutrophil interactions in ANCA-Associated diseases. J Am Soc Nephrol 2012; 23: 1449-1461.
220. Rodriguez-Pla A and Monach PA. Primary angiitis of the central nervous system in adults and children. Rheum Dis Clin North Am 2015; 41: 47-62, viii.
221. SNEDDON IB. Cerebro-vascular lesions and livedo reticularis. Br J Dermatol 1965; 77: 180-185.
222. Lewandowska E, Wierzba-Bobrowicz T, Wagner T, et al. Sneddon?s syndrome as a disorder of small arteries with endothelial cells proliferation: ultrastructural and neuroimaging study. Folia Neuropathol 2005; 43: 345-354.
223. Gobert A. Sneddon?s syndrome with bilateral peripheral retinal neovascularization. Bull Soc Belge Ophtalmol 1995; 255: 85-90.
224. Rehany U, Kassif Y and Rumelt S. Sneddon?s syndrome: neuro-ophthalmologic manifestations in a possible autosomal recessive pattern. Neurology 1998; 51: 1185-1187.
225. Basu N, Murray AD, Jones GT, et al. Neural correlates of fatigue in granulomatosis with polyangiitis: a functional magnetic resonance imaging study. Rheumatology (Oxford) 2014; 53: 2080-2087.
226. Nagel MA and Gilden D. Update on varicella zoster virus vasculopathy. Curr Infect Dis Rep 2014; 16: 407.
227. Fletcher NF, Wilson GK, Murray J, et al. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 2012; 142: 634-643.e6.
228. Chetty R. Vasculitides associated with HIV infection. J Clin Pathol 2001; 54: 275-278.
229. Sen S, Rabinstein AA, Elkind MS, et al. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovasc Dis 2012; 33: 209-218.
230. Ortiz G, Koch S, Romano JG, et al. Mechanisms of ischemic stroke in HIV-infected patients. Neurology 2007; 68: 1257-1261.
231. Morgello S, Murray J, Van Der Elst S, et al. HCV, but not HIV, is a risk factor for cerebral small vessel disease. Neurol Neuroimmunol Neuroinflamm 2014; 1: e27.
232. Benjamin LA, Bryer A, Emsley HC, et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol 2012; 11: 878-890.
233. Gonzalez-Scarano F and Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
234. Moses AV, Bloom FE, Pauza CD, et al. Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism. Proc Natl Acad Sci USA 1993; 90: 10474-10478.
235. Kim TA, Avraham HK, Koh YH, et al. HIV-1 Tatmediated apoptosis in human brain microvascular endothelial cells. J Immunol 2003; 170: 2629-2637.
236. Niu F, Yao H, Zhang W, et al. Tat 101-mediated enhancement of brain pericyte migration involves platelet-Derived growth factor subunit B homodimer: implications for human immunodeficiency virus-Associated neurocognitive disorders. J Neurosci 2014; 34: 11812-11825.
237. Miklossy J. Biology and neuropathology of dementia in syphilis and Lyme disease. Handb Clin Neurol 2008; 89: 825-844.
238. May EF and Jabbari B. Stroke in neuroborreliosis. Stroke 1990; 21: 1232-1235.
239. Silva J, Polesskaya O, Knight W, et al. Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5. J Neuroinflamm 2012; 9: 253.
240. Fallon BA, Lipkin RB, Corbera KM, et al. Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy. Arch Gen Psychiatry 2009; 66: 554-563.
241. Nagy Z and Czirjak L. Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud?s disease. J Eur Acad Dermatol Venereol 2004; 18: 62-68.
242. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud?s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902-3912.
243. Amaral TN, Peres FA, Lapa AT, et al. Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum 2013; 43: 335-347.
244. Heron E, Fornes P, Rance A, et al. Brain involvement in scleroderma: two autopsy cases. Stroke 1998; 29: 719-721.
245. Nobili F, Cutolo M, Sulli A, et al. Impaired quantitative cerebral blood flow in scleroderma patients. J Neurol Sci 1997; 152: 63-71.
246. Cutolo M, Nobili F, Sulli A, et al. Evidence of cerebral hypoperfusion in scleroderma patients. Rheumatology (Oxford) 2000; 39: 1366-1373.
247. Jimenez C, Rowe PC and Keene D. Cardiac and central nervous system vasculitis in a child with dermatomyositis. J Child Neurol 1994; 9: 297-300.